{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T11:35:42Z","timestamp":1779363342361,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To report thrombocytopenia in a patient prescribed thalidomide for multiple myeloma (MM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY<\/jats:title>\n                    <jats:p>\n                      A 70-year-old woman was diagnosed in 2003 with MM. At diagnosis, melphalan 0.25 mg\/kg\/day and prednisolone 2 mg\/kg\/day were started; however, the patient became refractory to therapy. Melphalan and prednisolone were discontinued, and monotherapy with dexamethasone 40 mg for 12 days per month was started. The patient's hematologic condition deteriorated again after about one year; dexamethasone was discontinued, and treatment with oral thalidomide 200 mg\/day was initiated. About 2 weeks after thalidomide administration, the woman developed disabling adverse effects (flu-like symptoms, swollen fingers, rash and hematoma on her legs, shortness of breath, dry mouth, multiple petechiae). Laboratory testing showed neutropenia (neutrophils 0.4 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L) and thrombocytopenia (platelets 58 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L). Thalidomide was promptly discontinued; within 3 weeks, the laboratory values returned to pretreatment levels (1.3 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L and 267 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L, respectively) and her symptoms disappeared.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Thrombocytopenia is a rarely reported hematologic adverse consequence of thalidomide therapy. A recent report identified 5 patients who developed thrombocytopenia while undergoing monotherapy with thalidomide for MM. According to the Naranjo probability scale, thalidomide was classified as the probable cause of thrombocytopenia in our patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Unlike other antineoplastic drugs, thalidomide is rarely reported to cause severe hematologic toxicity. We present this case to increase clinicians\u2019 awareness for the potential of thalidomide to adversely affect platelet counts, particularly because its effectiveness in MM will likely result in expansion of its clinical use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g256","type":"journal-article","created":{"date-parts":[[2005,10,11]],"date-time":"2005-10-11T23:23:42Z","timestamp":1129073022000},"page":"1936-1939","source":"Crossref","is-referenced-by-count":7,"title":["Thalidomide-Associated Thrombocytopenia"],"prefix":"10.1177","volume":"39","author":[{"given":"Michiel","family":"Duyvendak","sequence":"first","affiliation":[{"name":"Michiel Duyvendak MPharm, Hospital Pharmacist, Department of Clinical Pharmacy, Tjongerschans Hospital, Heerenveen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Naunton","sequence":"additional","affiliation":[{"name":"Mark Naunton BPharm (Hons) PhD, Visiting Research Fellow, Department of Clinical Pharmacy, Tjongerschans Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert J","family":"Kingma","sequence":"additional","affiliation":[{"name":"Bert J Kingma MD, Internist, Department of Internal Medicine, Tjongerschans Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus RBJ","family":"Brouwers","sequence":"additional","affiliation":[{"name":"Jacobus RBJ Brouwers PhD, Professor, Department of Pharmacotherapy and Pharmaceutical Care, State University of Groningen, Groningen, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"bibr1-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1177\/107327480301000504"},{"key":"bibr2-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199402173300709"},{"key":"bibr3-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"bibr4-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2846"},{"key":"bibr5-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.2.492"},{"key":"bibr6-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.03.040"},{"key":"bibr7-aph.1G256","first-page":"472","volume-title":"Oncology book part 1","author":"van den Berg WN","year":"2002"},{"issue":"2","key":"bibr8-aph.1G256","first-page":"147","volume":"15","author":"Duval M","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"bibr9-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1532\/IJH97.03136"},{"key":"bibr10-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.40.6.2302-2304.2002"},{"key":"bibr11-aph.1G256","first-page":"368","volume":"44","author":"Okikawa Y","year":"2003","journal-title":"Rinsho Ketsueki"},{"key":"bibr12-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-4520.2004.00025.x"},{"key":"bibr13-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr14-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197402000-00008"},{"key":"bibr15-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1136"},{"key":"bibr16-aph.1G256","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2004.12.031"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1G256","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:09:24Z","timestamp":1777374564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":16,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1345\/aph.1G256"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g256","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}